Prior to serving as Alios' founder and CEO, Blatt held an array of scientific and leadership positions in the biopharmaceutical industry. Among other positions, he served as chief scientific officer of InterMune, where his work led to the development of Danoprevir, a groundbreaking peptidomimetic inhibitor. He also served as vice president of research of Sirna/Ribozyme at Amgen and as vice president of product development at the National Genetics Institute.
In addition to his bachelor's degree from Indiana University, Blatt earned a Ph.D. in public health administration from the University of La Verne and an MBA from California State University, Northridge. An avid guitarist and composer, he's also released several award-winning instrumental albums.